ENDECE has developed NDC-1308, a therapeutic agent that inhibits SARS-CoV-2 replication in the pulmonary system and reduces inflammation in patients with Acute Respiratory Distress Syndrome (ARDS). This treatment addresses the high mortality rate associated with ARDS by providing a targeted approach to a condition with limited therapeutic options.
Funding
$1.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Acute Respiratory Distress Syndrome (ARDS) is associated with high mortality rates and limited therapeutic options. Current treatments often fail to adequately address both the SARS-CoV-2 replication in the pulmonary system and the excessive inflammation contributing to lung injury. This unmet need highlights the necessity for more targeted and effective interventions.
Solution
ENDECE is developing NDC-1308, a therapeutic agent designed to inhibit SARS-CoV-2 replication within the pulmonary system while simultaneously reducing inflammation in patients suffering from ARDS. NDC-1308 exhibits a dual mechanism-of-action, inducing remyelination and inhibiting demyelination, differentiating it from other Multiple Sclerosis drugs. The drug upregulates the expression of the gene for lipoprotein lipase (LPL) within macrophages, causing their polarization to the M2, anti-inflammatory, pro-repair state. This novel approach aims to provide a more comprehensive treatment strategy by targeting both the viral infection and the associated inflammatory response, potentially improving patient outcomes and reducing mortality. NDC-1308 is also being investigated as a treatment for neurodegenerative diseases.
Target Audience
The primary target audience includes patients suffering from ARDS, COVID-19, Multiple Sclerosis, Alzheimer’s Disease, Neuromyelitis Optica Spectrum Disorder, Niemann-Pick disease type C, and Osmotic Demyelination Syndrome, as well as healthcare providers specializing in pulmonary and neurodegenerative diseases.
Features
- Inhibits SARS-CoV-2 replication in the pulmonary system.
- Reduces inflammation associated with ARDS.
- Induces remyelination of demyelinated axons within the CNS.
- Protects the CNS from demyelination for a prolonged time.
- Upregulates the expression of the gene for lipoprotein lipase (LPL) within macrophages.
- Promotes macrophage polarization to the M2, anti-inflammatory, pro-repair state.